Onesource Specialty Pharma Ltd.
NSE: ONESOURCEOnesource Specialty Pharma Ltd.: A 30-second snapshot
OneSource Specialty Pharma is a CDMO-focused pharma company trading at ₹1,819.9, up 52.52% over 3 months and 14.38% over 1 year, with the stock above both its 50-DMA (₹1,557) and 200-DMA (₹1,667). The fundamental profile is materially weak — D/E of 21.93, profit margin of 1.42%, 0 FCF-positive years on record, and a 26% five-year revenue contraction — while recent news flow centres on GLP-1 CDMO partnerships and an EU-GMP renewal that the market appears to be pricing as a forward inflection point.
P/E
—
Forward P/E
23.9
ROE
—
Debt / Equity
21.93
Profit Margin
+1.4%
Div. Yield
—
5Y ROE > 15%
0/5
5Y FCF > 0
0/5
Quality
41/100
News
8 headlines · 6 positive · 1 negative
OneSource Specialty Pharma Board Decides Against Pursuing Composite Merger Scheme in Current Form - scanx.trade
scanx.trade
Dr. Reddy's Labs Bags Health Canada Nod for Ozempic Generic, OneSource to Scale Supply - Medical Dialogues
Medical Dialogues
OneSource Strengthens CDMO Play as Partner Secures USFDA Tentative Approval for Ozempic Generic - Medical Dialogues
Medical Dialogues
OneSource Specialty Pharma secures EU-GMP renewal for Bengaluru unit II facility - CNBC TV18
CNBC TV18
OneSource Specialty Pharma: A capacity-led bet on the GLP-1 gold rush - The Indian Express
The Indian Express
Recent context
- ·On 14 May 2026, the OneSource board decided against pursuing a composite merger scheme in its current form, introducing unresolved questions about the company's consolidation strategy.
- ·Dr. Reddy's secured Health Canada approval for an Ozempic generic (April 2026), with OneSource cited as a supply partner — representing a concrete milestone in its GLP-1 CDMO positioning.
- ·The company received EU-GMP renewal for its Bengaluru Unit II facility (April 2026), maintaining regulatory clearance for European export markets.
Strengths
- +Price is 16.9% above its 200-DMA (₹1,667) and 16.9% above its 50-DMA (₹1,557), with RSI at 65.08 — within the neutral zone despite the sharp 3-month run.
- +52-week drawdown of 19.04% is relatively contained compared to peers, and the stock has recovered to within 19% of its 52-week high.
- +Recent regulatory milestones include EU-GMP renewal for the Bengaluru Unit II facility and CDMO partnerships tied to GLP-1 (Ozempic generic) supply scaling, which represent verifiable operational developments.
- +Forward PE of 23.89 is below the peer range for large-cap pharma (Cipla 29.8, Dr. Reddys 26.6, Sun Pharma 41.3), suggesting current valuation does not yet embed large-cap multiples.
Weaknesses
- −D/E of 21.93 is extremely elevated relative to pharma/CDMO sector norms; combined with 0 FCF-positive years on record, the balance sheet carries material solvency risk if the anticipated revenue turnaround stalls.
- −Five-year revenue growth of -26% and a profit margin of just 1.42% indicate that the business has not yet demonstrated the earnings quality that the current price momentum implies.
- −Quality score of 34 ranks 4th of 6 in the Pharma peer set, with a consistency score of 25; MAXHEALTH (54) and SUNPHARMA (50) show materially stronger operational track records.
- −The board recently decided against pursuing a composite merger scheme in its current form — a corporate action development that introduces uncertainty around the company's strategic direction.
Open questions
- ?Does the 26% five-year revenue contraction reflect a deliberate portfolio restructuring toward higher-margin CDMO contracts, or an ongoing loss of market share in legacy businesses?
- ?At a D/E of 21.93 with 0 FCF-positive years on record, what is the timeline and mechanism by which the company's debt servicing obligations are expected to be met?
- ?How dependent is the GLP-1 CDMO revenue opportunity on a single partner (Dr. Reddy's), and what contractual protections exist if that partnership changes?
- ?The board rejected the merger scheme in its current form — what alternative strategic paths are under consideration, and how do they affect the capital structure?
Peer comparison: Pharma
Ranks 4 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| ONESOURCE | Onesource Specialty Pharma Ltd.You're viewing | — | — | 34 |
| Industry avg | across 5 peers | 47.0 | +11.8% | 37 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 72.5 | — | 54 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.3 | — | 50 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 64.6 | — | 42 |
| CIPLA | Cipla Ltd. | 29.8 | +11.7% | 24 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 26.6 | +11.8% | 17 |
Technical state
Current price
₹1,819.90
SMA 50
₹1,557.15
SMA 200
₹1,666.61
RSI (14)
65.1 (neutral)
From 52w high
-19.0%
1Y return
+14.4%
3M return
+52.5%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- highDebt-to-equity of 21.93 is extremely elevated for a pharma/CDMO company (sector peers such as Cipla and Dr. Reddys carry D/E well below 1); combined with 0 FCF-positive years in the available history and a 5-year revenue decline of 26%, the balance sheet carries material solvency risk.
- highFive-year revenue growth of -26%, profit margin of 1.42%, 0 ROE years above 15%, and 0 FCF-positive years indicate no demonstrated earnings quality; the forward PE of 23.89 embeds expectations of a substantial operational turnaround that the historical record does not yet support.
- mediumA 52.52% price gain over 3 months has brought the stock (₹1,819.9) within 0.2% of the nearest resistance at ₹1,824, with RSI at 65.08; the nearest support cluster sits at ₹1,316–₹1,258, representing a 28–31% drop from current levels.
- mediumQuality score of 34 ranks 4th of 6 in the Pharma peer set; MAXHEALTH (54) and SUNPHARMA (50) score materially higher, and the consistency score of 25 is among the weakest in the peer group.
- lowAnalyst coverage is thin at 4 analysts; mean rating of 1.75 on a 1–5 scale (lower = more constructive) carries limited statistical reliability at this sample size.
Cross-section contradictions
- Fundamental profile shows 0 FCF-positive years, D/E of 21.93, and a 5-year revenue contraction of 26%, yet the stock has gained 52.52% over 3 months and trades at a forward PE of 23.89 — price action that prices in a structural inflection the historical financials have not yet delivered.
- News sentiment is positive (6 of 8 articles) driven by CDMO and GLP-1 partnership narratives, but the underlying profit margin stands at 1.42% and no free cash flow has been generated across the available history.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 25 Jun 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 15 May 2026 · rotates through NIFTY 500 every ~5 days